Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
作者机构：Department of Medical OncologyLinyi Cancer HospitalLinyi 276002China Department of Thoracic Medical OncologyJilin Cancer HospitalChangchun 130012China Department of Internal MedicineAffiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhou 450003China Department of Pulmonary OncologyTianjin Medical University Cancer Institute and HospitalTianjin 300060China Department of Thoracic Medical OncologyThe Affiliated Cancer Hospital of Xiangya School of MedicineCentral South University(Hunan Cancer Hospital)Changsha 410031China Department of Respiratory MedicineShanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030China Department of Respiratory MedicineHarbin Medical University Cancer HospitalHarbin 150081China Department of Thoracic SurgeryThe First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou 510120China National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Pulmonary OncologyThe Fifth Medical Centre of Chinese PLA General HospitalBeijing 100039China Department of Medical OncologyLiaoning Cancer HospitalShenyang 110042China
出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)
年 卷 期：2022年第16卷第5期
页 面：766-772页
核心收录：
学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学]
基 金：This study was supported by the Jilin Provincial Healthand Family Planning Commission (No.2019J077) the Science and Technology Agency of Jilin Provincial Project (No.20200201518JC)。
主 题：anlotinib chemotherapy short-term relapsed small-cell lung cancer
摘 要：Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing ≥ two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gamma-glutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard.
维普期刊数据库